What Researchers Did
Researchers retrospectively evaluated the outcomes of intralesional epidermal growth factor (EGF) therapy in 15 patients with diabetic foot ulcers.
What They Found
They found that 13 patients (86.7%) developed new granulation tissue, and 10 patients (66.7%) achieved complete wound closure, while 3 patients (20%) had partial closure. No serious side effects requiring discontinuation of EGF therapy were observed.
What This Means for Canadian Patients
This therapy could potentially offer a new option for Canadian patients struggling with diabetic foot ulcers, helping to accelerate healing and reduce wound closure time. Patients might experience improved wound healing without significant adverse effects.
Canadian Relevance
This study was conducted in Turkey and does not have a direct Canadian connection.
Study Limitations
The study's small sample size of 15 patients and its retrospective, single-center design limit the generalizability of these findings.